Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 4Phase 1/2 1Phase 1 1

Status

Completed 13Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasms 281Carcinoma, Non-Small-Cell Lung 251Leukemia, Myeloid, Acute 189Breast Neoplasms 151Melanoma 150Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 113Lymphoma 112Leukemia, Lymphocytic, Chronic, B-Cell 107Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 85Prostatic Neoplasms 83Lung Neoplasms 81Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 67Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 49

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Thyroid Cancer, Papillary × Clear all
NCT03469011 2025-06-27

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

AHS Cancer Control Alberta

Phase 1 Terminated
14 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡